The news on Pharma Business

94 days ago

There has been 15 news on Pharma Business in the past from 7 different sources and amongst 3 sections.

Full access to all news in this scope:

See the trend on this scope:

Evolution through time

Latest news

Ozempic 2.0, the Oura ring's new trick, and RFK Jr. vs. vaccines: Pharma news roundup

Quartz link
94 days ago

Supreme Court rejects appeal from 'Pharma Bro' Martin Shkreli

The Washington Times link
139 days ago

How techbio is shaking up pharma

Fast Company link
161 days ago

Telehealth's bet on cheap off-brand weight loss drugs is putting pressure on Big Pharma to lower prices

Quartz link
179 days ago

Martin Shkreli, infamous "Pharma Bro," must surrender his one-of-a-kind Wu-Tang Clan album

LA Times link
180 days ago

Fake weight loss drugs, and Novo Nordisk's CEO will face Bernie Sanders: Pharma news roundup

Quartz link
248 days ago

'Pharma Bro' Martin Shkreli accused of copying, sharing one-of-a-kind Wu-Tang Clan album

The Washington Times link
257 days ago

Ozempic competitors, psychedelic stocks, and Moderna after COVID: Pharma news roundup

Quartz link
262 days ago

Pharma exports grew 10% to $28 billion in FY24, poised to hit $31 billion in FY25: Pharmexcil

Times of India link
269 days ago

Ozempic knockoffs, Pfizer's cost-cutting, and AstraZeneca's future: Pharma news roundup

Quartz link
276 days ago

Fake Ozempic sites, more Zepbound shortage, and J&J 's sales miss: Pharma news roundup

Quartz link
311 days ago

GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost

CNBC News link
390 days ago

Appeals court bans 'Pharma Bro' Martin Shkreli from working in pharmaceuticals ever again

The Washington Times link
396 days ago

Bernie Sanders Wants a Pharma CEO Show Trial

Sections

The coverage spreads amongst 3 sections:

business 13%
culture 13%
health 33%

Sources

There has been 7 news sources reporting on this, including: Quartz (40%), The Washington Times (27%), LA Times (7%), Times of India (7%), CNBC News (7%).

Going further

Stay up to date:

Details

This content can be used under the CC BY 4.0 license